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MICHELLE SHERMAN PRATT 
 
ABSTRACT 
 
 There are unmet needs in evaluating treatment response of hepatocellular 
carcinoma in research protocols. Early predictors, such as imaging biomarkers, could 
allow for earlier judgment of treatment effect. Currently RECIST is the most widely 
accepted criterion in clinical trials. A modified RECIST (mRECIST) criterion was 
developed to take into account the unique imaging characteristics of HCC lesions. Much 
discussion has occurred regarding linear measurements and their appropriateness for 
evaluating change in tumor burden over time. The simplicity of currently accepted 
criteria differs with the increasing sophistication of imaging techniques. Tumor volume 
change on 3D imaging can provide insight into actual action of treatment rather than an 
estimate of action as shown by linear and bi-dimensional measurements. It was the aim of 
this study to determine whether linear, bi-dimensional, and volumetric percent changes of 
HCC lesions, in both the arterial and portal venous phases, are significantly comparable.  
27 HCC lesions (identified on 25 subjects) were measured at two timepoints by 
each method on 3D GRE MRI scans in both phases. Percent change was calculated per 
  vii
lesion for each measurement type in both the arterial and portal venous phases. Signed 
rank tests, paired t tests, and comparison of change tests were run to evaluate the data. 
Significant differences between the percent changes of linear measurements 
versus volumetric measurements were observed using a Wilcoxon signed-rank test which 
showed p = 0.0000. A simple correlation assessment showed positive correlations for all 
measurements, with the lowest being correlations 0.8679 for the arterial linear percent 
change versus the arterial volumetric percent change and 0.8434 for the portal venous 
linear percent change versus the portal venous volumetric percent change. Differences 
between percent changes of linear versus bi-dimensional measurements and bi-
dimensional versus volumetric measurements were significant as well (Linear versus bi-
dimensional p = 0.0001, bi-dimensional versus volumetric p = 0.0004). 
To conclude, the differences in the percent changes when comparing the 
measurement types are statistically significant, particularly when comparing linear and 
volumetric measurements. Establishing a reproducible volumetric criterion could lead to 
improvements in the implementation of clinical trials.  
 
  
  viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES ........................................................................................................... xi 
LIST OF ABBREVIATIONS ........................................................................................... xii 
INTRODUCTION .............................................................................................................. 1 
Risk Factors ............................................................................................................... 1 
Current Treatments .................................................................................................. 3 
Imaging and HCC ..................................................................................................... 5 
Evaluation Criteria ................................................................................................... 7 
METHODS ....................................................................................................................... 10 
Subject selection ...................................................................................................... 10 
Quantitative analysis: tumor size measurement .................................................. 11 
  ix
Statistical analysis ................................................................................................... 21 
RESULTS ......................................................................................................................... 22 
Comparison of linear, bi-dimensional and volumetric percent changes ........... 22 
Comparison of arterial and portal venous percent changes ............................... 23 
DISCUSSION ................................................................................................................... 24 
LIST OF JOURNAL ABBREVIATIONS........................................................................ 34 
REFERENCES ................................................................................................................. 35 
CURRICULUM VITAE ................................................................................................... 40 
 
  
  x
LIST OF TABLES 
 
 
Table Title Page 
1 Days between scans 10 
2 Treatments subjects received between scans 11 
3a Linear, bi-dimensional and volumetric lesion 
measurements on scans in the arterial phase 
 
13 
3b Linear, bi-dimensional and volumetric lesion 
measurements on scans in the portal venous phase 
 
15 
3c Summary of measurement data 
 
17 
4a Percent changes of linear, bi-dimensional and volumetric 
measurements between scans in the arterial and portal 
venous phases for each lesion 
 
19 
4b Summary of percent change data 20 
5 Wilcoxon signed-rank test results 22 
6 Correlations 23 
 
 
  
  xi
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Risk factors for the development of hepatocellular 
carcinoma 
 
3 
2 HCC lesion showing typical arterial contrast enhancement 
and portal venous washout on 3D-GRE MRI 
 
6 
3 Linear, bi-dimensional and volumetric measurements on 
the arterial phase and the portal venous phase 
 
12 
4 Differences in percent changes between measurement 
types 
 
27 
5 Differences in percent changes between phases 32 
  
  xii
LIST OF ABBREVIATIONS 
 
A……………………………………………………………………………………Arterial 
ANOVA………………………………………………………………Analysis of variance 
AW………………………………………………………………...Advantage Workstation 
cm3……………………………………………………………………...Centimeters cubed 
BMC………………………………………………………………..Boston Medical Center 
CT…………………………………………………………………Computed Tomography 
GE…………………………………………………………………………General Electric 
GRE…………………………………………………………………………Gradient Echo 
HBV…………………………………………………………………………….Hepatitis B 
HCC……………………………………………………….…….Hepatocellular carcinoma 
HCV…………………………………………………………………………….Hepatitis C 
I-HCC… ………………………………………....….Infiltrative hepatocellular carcinoma 
mm……………………………………………………………………………...Millimeters 
mm2……………………………………………………………………Millimeters squared 
mRECIST……………………….Modified Response Evaluation Criteria in Solid Tumors 
MRI…………………………………………………………Magnetic Resonance Imaging 
NAFLD…………………………………………………..Non-alcoholic fatty liver disease 
NASH………………………………………………………..Non-alcoholic steatohepatitis 
OLT……………………………………………………….Orthotopic liver transplantation 
OS…………………………………………………………………………Overall Survival 
PACS……………………………………………Picture archiving communication system 
  xiii 
PEI…………………………………………………………Percutaneous ethanol injection 
PPD………………………………………………..Product of the perpendicular diameters 
PD……………………………………………………………………..Progressive Disease 
PR…………………………………………………………………………Partial Response 
Prob……………………………………………………………………………..Probability 
PV……………………………………………………………………………Portal Venous 
RECIST……………………………………Response Evaluation Criteria in Solid Tumors 
RFA………………………………………………………………Radiofrequency ablation 
SD…………………………………………………………………………...Stable Disease 
SPPD…………………………………Sum of the products of the perpendicular diameters 
TACE…………………………………………..Transcatheter arterial chemoembolization 
TAE…………………………………………………………….Transarterial embolization 
THRIVE……………………..T1-weighted high-resolution isotropic volume examination 
TTP……………………………………………………………………Time to Progression 
US……………………………………………………………………………….Ultrasound 
USA…………………………………………………………...…United States of America 
WHO…………………………………………………………..World Health Organization
 1 
INTRODUCTION 
 
 Hepatocellular Carcinoma (HCC) is the fifth most common tumor type in 
the world and the most common primary malignancy of the liver. Liver cancer is the third 
leading cause of cancer-related deaths in the world, more prevalent in men than 
women.1,2 The prognosis of a patient with HCC is poor with a five-year survival rate of 
approximately 12%.3 The mortality rate has been steadily growing over the last three 
decades and in the United States (USA) alone the incidence has tripled.4 This disease has 
the fastest growing mortality rate of all cancers in the USA and the increase of new cases 
in younger patients is concerning as the mean age of diagnosis is mid to late 50s.3,5 The 
global incidence is heterogeneous and is dependent on risk factor variations throughout 
the continents; however, the highest burdens are seen in developing countries2,6. 
HCC begins in hepatocytes, usually arising in the cirrhotic liver.7 Most cases of 
HCC develop stepwise from a low-grade dysplastic nodule to a high-grade dysplastic 
nodule, then to a dysplastic nodule with a focus on HCC, and lastly carcinoma.8 They are 
highly vascular tumors that receive their blood supply from the hepatic artery unlike most 
liver tissue which is supplied blood from the portal vein.9 These tumors show aggressive 
growth, frequently metastasize and often recur after treatment.10 
Risk Factors 
The precursors to cirrhosis are major risk factors for HCC as approximately 80% 
of cases develop in cirrhotic livers. In the USA and developed countries, cirrhosis of the 
liver is present in most patients with HCC.11 In these countries; there has been a rise of 
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alcohol related cirrhosis due to an increase in chronic alcohol use. Hepatitis B (HBV) is 
the leading risk factor globally with more than half of the world’s tumor burden attributed 
to this infection. The under-developed world (East-Asia and Sub-Saharan Africa) has a 
high incidence of HBV. Hepatitis C (HCV) also increases the risk of HCC although it 
takes approximately 20 years for cirrhosis to develop after contracting HCV, so the 
timing of the viral infection is important to take into consideration.11,13 As the incidence 
of HCV has increased in the developed world, so has the incidence of HCC.1,5,10,12 Risk is 
higher among males with HBV and/or HCV infections, especially if they are elderly.13 
 A risk factor that has a high prevalence in developed parts of the world, 
particularly the United States, is non-alcoholic fatty liver disease (NAFLD). NAFLD 
causes the development of non-alcoholic steatohepatitis (NASH) and cirrhosis, which can 
lead to HCC. NAFLD is being diagnosed more frequently in patients with obesity and 
type-2 diabetes. As a leading cause of chronic liver disease in these developed countries, 
NAFLD may become one of the leading causes of HCC as the incidence of obesity and 
type-2 diabetes continue to rise.11,13,14,15 
 There are a number of other risk factors that have been studied in association with 
HCC. As previously mentioned alcohol use is a cause of cirrhosis and may be a 
significant risk factor of HCC, especially in geographic areas where there is low 
HBV/HCV infection.14 Additionally, dietary aflatoxin, a toxic metabolite created by 
certain fungi, is a carcinogen and there is a high incidence of HCC in areas where there is 
regular consumption of contaminated food, particularly in sub-Sahara Africa, South-East 
Asia, and China.1,14 Genetic haemochromatosis is a metabolic disorder that causes iron-
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overload, which may also be a risk factor of HCC, although the carcinogenicity of iron is 
still under debate.16 Furthermore, any other cause of cirrhosis could be a risk factor to 
HCC and the combination of any cirrhosis risk factors could increase the risk of HCC 
(Fig.1). 
 
 
Figure 1: Risk factors for the development of hepatocellular carcinoma.
15
 
 
Current Treatments 
 Classification of HCC can be challenging as it is a largely heterogeneous 
malignancy. In order to determine an appropriate treatment, factors such as tumor burden 
and underlying cirrhosis or hepatic dysfunction must be taken into consideration, 
especially because cirrhosis puts the patient at risk for new primary tumors even while 
the current tumor burden is being treated.17  
Early stage HCC is the only solid tumor that can be treated by orthotopic liver 
transplantation (OLT) with the possibility of being cured, as this procedure requires 
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removing the subject’s liver and replacing it with a donor liver. There are strict criteria 
used to decide if a subject is eligible for this treatment as donor organs are scarce. 
Surgical resection is also available for subjects without cirrhosis and this can potentially 
be curative, however only a small percentage of subjects are eligible for these treatments 
due to HCC multifocality on a background of chronic liver disease. For patients with 
intermediate stage HCC, there are a number of treatments available that are non-curative 
but they degrade the tumor while keeping the other liver tissue intact. For HCC with 
multifocal lesions without vascular invasion, transcatheter arterial chemoembolization 
(TACE), with or without drug eluting beads, or transarterial embolization (TAE) are 
appropriate options as they are minimally invasive procedures that can be used to directly 
cut off a tumors blood supply. Locoregional therapies such as percutaneous ethanol 
injection (PEI), cryotherapy, and radiofrequency ablation (RFA) are also available to 
treat early stage disease.6 
A number of drug treatments have been developed and have gone through clinical 
trials; however Sorafenib, approved by the FDA in 2007, is the first agent that has shown 
improved overall survival (OS) benefits in advanced HCC.12 It targets two of the key 
pathways that play an important role in the pathogenesis of HCC.18 Further study of this 
drug is needed as the clinical benefits have only been seen in certain patients. HCC 
tumors generally have a low response rate to chemotherapy as they have high resistance 
to drugs and there is difficulty getting the drug into the tumor. Previously there was no 
effective treatment available for the advanced stage of this disease or for subjects who 
progressed to the advanced stage after other treatments failed.18 Sorafenib stabilizes the 
 5 
tumor by delaying progression, however while it does improve OS, progressive disease 
eventually develops in most patients.17  
 
Imaging and HCC 
Medical imaging is useful for HCC diagnosis, as patients typically do not present 
with symptoms until later stages of the disease. Ultrasound (US) is the first line 
diagnostic method for HCC, however, cirrhosis can complicate detection and lesions can 
be missed.19 Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are 
the current preferred modalities for identifying HCC as they provide a clear and detailed 
picture of internal anatomy. 
Arterial enhancement is considered an essential characteristic of HCC and is used 
as a main imaging characteristic for HCC diagnosis. During the arterial phase, most of 
the liver is not yet enhancing because 75% of the liver’s blood supply will arrive later via 
that portal vein. HCC, however, shows pronounced enhancement during the arterial phase 
due to the source of the tumor tissue blood supply.7 Enhancement tends to be 
heterogeneous in large lesions and more homogeneous in smaller ones. A mosaic pattern 
is created by confluent nodules separated by fibrosis septa and areas of necrosis.19 The 
most common appearance of HCC is early arterial contrast enhancement with “washout” 
on delayed phases. On the portal venous phase there is also relative hypoenhancement 
compared to surrounding liver parenchyma with a delayed enhancing outer rim “capsule” 
(Fig. 2).15 
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Figure 2: HCC lesion showing typical arterial contrast enhancement (left) and portal 
venous washout (right) on 3D-GRE MRI. 
 
CT with contrast can identify HCC lesions based on early arterial enhancement 
and late portal venous washout. MRI (with contrast) is sensitive for the detection of 
lesions measuring 2cm or larger but is less sensitive for the diagnosis of small HCC 
lesions.19 Tumors are generally bright on T1-weighted sequences mainly attributed to the 
presence of intratumoral fat, copper deposition within the tumor and the degree of 
differentiation, presence of fibrosis, and intratumoral necrosis19,20. Also, intratumoral 
hemorrhage, coagulative necrosis and mucin production can make signal intensity 
mixed.21 There is moderately high tumor signal intensity on T2-weighted sequences; 
however it can be difficult to detect lesions on T2 because of the heterogeneity of the 
cirrhotic liver.8 MRI also provides structural information on unenhanced images. 
3D-GRE is a MRI imaging technique with a fast acquisition time.22 This 
volumetric MRI technique can image the entire volume of the tissue simultaneously, 
allowing for efficient imaging by acquiring thinner sections and covering the anatomy of 
interest in reduced time.7 This imaging provides detailed anatomical information and 
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good spatial resolution with an acceptable acquisition time for assessment of tumor size; 
however, it does not show partial volume averaging artifacts which can make it difficult 
to assess disease due to blurring.23 
 
Evaluation Criteria 
Evaluation of tumor response is critical for determining whether a particular 
treatment is effective in a patient, or whether an experimental agent is effective against a 
specific tumor type. Many cancer related deaths are actually due to delayed tumor 
evaluation.39 The accurate and early prediction of response or progression, while 
important for treating patients, is critical to clinical trials. For example, HCC clinical 
trials often use Time to Progression (TTP) as a primary endpoint.40 Early predictors, such 
as imaging biomarkers, could allow for earlier judgment of treatment effect, which may 
allow for faster approval of new drugs and reduced time to market. It may also help to 
limit the size of trials, requiring lower subject enrollment and lower cost.41 
There are unmet needs with regards to evaluating treatment response of HCC in 
research protocols as well as in clinical practice, as management of patients is influenced 
by the response to treatment. Patients are typically without symptoms until the late stages 
of disease so the assessment of tumor burden via imaging is an important endpoint.24 
Currently the most commonly used imaging biomarker is the linear measurement of the 
tumor burden. The Response Evaluation Criteria in Solid Tumors (RECIST) is the most 
widely accepted criterion in clinical trials. It uses the sum of the largest diameters of each 
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lesion on the axial plane to calculate percent changes of the tumor burden. Response 
determinations are based on these percent changes.25  
HCC lesions have unique imaging characteristics. A modified RECIST 
(mRECIST) criterion was developed to take these characteristics into account. mRECIST 
takes into account only viable tumors seen on contrast enhanced imaging. A viable tumor 
is defined as tumor tissue with arterial enhancement and portal venous washout. Linear 
measurements made on arterial phase axial images are used in this criterion to determine 
percent changes of tumor diameters between exams as the authors believe that the lesions 
are more accurately measured while enhanced.26 
There has been, and continues to be, much discussion regarding linear 
measurements and their appropriateness for evaluating tumor burden and changes 
between timepoints.47 In 1979, the first guidelines were proposed by the World Health 
Organization (WHO) using bi-dimensional measurements and assessing responses using 
the change in the sum of the products of the perpendicular diameters (SPPD).27 In 2000 
the RECIST criterion was published with the rationale that it would provide a quicker and 
simpler assessment of tumor response to treatment.25 The simplicity of this criterion, 
developed almost 15 years ago, but still widely used today, differs with the increasing 
sophistication of imaging instruments. Volumetric imaging allows for precise 3D 
measurement of the entire tumor burden. 
Quantification of tumor burden can be accurately performed using volumetric 
acquisitions.28 Tumor volume change can provide insight into the actual effect of 
treatment rather than an estimate of action as shown by linear and bi-dimensional 
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measurements.42 There are, however, no widely accepted criteria using the percent 
changes of volumes to determine response.  
It was the aim of this study to answer the question: Are linear, bi-dimensional, 
and volumetric measurements of HCC lesions comparable for assessing change in tumor 
size?? The primary objective was to evaluate potential differences in the percent changes 
of the three different types of measurements. The secondary objective was to evaluate the 
potential differences in the measurements due to enhancement phase. The primary 
endpoint is the percent change of each measurement between the two scans. The 
hypothesis of this study was that there are significant differences in using linear, bi-
dimensional and volumetric measurements for calculating percent change of HCC lesions 
on MRI.
 10 
METHODS 
 
 
Subject selection 
This study was a retrospective cohort study. The 25 subjects included in this study 
were identified using Centricity Electronic Medical Records (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK) at Boston Medical Center (BMC). All of the subjects 
had at least one liver lesion with a longest diameter greater than 10mm that presented 
with the HCC characteristics of arterial phase enhancement and portal venous phase 
washout. These lesions had been previously identified by a BMC radiologist, per standard 
of care, and noted in the subject’s medical record. 3D GRE scans, per standard of care, 
were available for each subject from two separate dates (Scan 1 and Scan 2), with both 
arterial and portal venous phases included (Table 1). 
 
Table 1. Days between Scan 1 and Scan 2 
 
Min 1st Q Med 3rd Q Max Mean 
Days Between Scans 46 95 117 184 401 153 
 
 
 
All scans were performed between 2008 and 2013 on a Philips MRI (Philips, Amsterdam, 
The Netherlands).  The treatment that the subjects received between scans was identified 
from the medical records. 18 subjects had received no treatment, 4 subjects were treated 
with Nexavar, 1 subject was treated with chemoembolization, 1 subject had an 
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unsuccessful chemoembolization and intermittent Sorafenib, and 1 subject’s treatment is 
Unknown (Table 2). All these treatments were per standard of care.  
 
Table 2. Treatments subjects received between Scan 1 and Scan 2 
 
Treatment Number of Subjects % of subjects 
None 18 72% 
Nexavar (Sorafenib) 4 16% 
Chemoembolization 1 4% 
Unsuccessful 
chemoembolization, 
intermittent Sorafenib 
1 4% 
Unknown 1 4% 
 
 
 
Quantitative analysis: tumor size measurement 
All subject imaging was reviewed on a BMC GE AW Workstation (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK ), which accessed the images from the 
picture archiving communication system (PACS). For the purpose of this study, a single 
reviewer, using AW VolumeShare 4 software, identified 27 lesions that were appropriate 
for linear, bi-dimensional, and volumetric measurements. Each lesion was measured on 
two 3D GRE scans, on both the arterial and portal venous phase for each (Fig. 3). 
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Figure 3: Linear, bi-dimensional and volumetric measurements of lesion 2-1 on the arterial 
phase (right) and of lesion 6-1 on the portal venous phase (left).  
 
All measurements were made on the axial plane; however the sagittal and coronal planes 
were also available to view. The scans for each lesion were read in chronological order 
and were read without comparison to the other scan. The volume measurements were 
made by outlining the lesion on each axial slice and having the software calculate the 
volume in cm3. Subsequently, the maximum diameter in millimeters (mm) was measured 
for each lesion where the lesion was the largest. After this measurement was completed, 
the longest perpendicular measurement was made in mm on the same slice. The longest 
diameter and the longest perpendicular diameter were multiplied to get the product of the 
perpendicular diameters (PPD) in mm2 (Tables 3a & 3b). 
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Table 3a. Linear, bi-dimensional and volumetric lesion measurements on Scan 1 and Scan 2 
in the arterial phase 
 
Subject 
Number 
Scan 
Lesion 
# 
Arterial 
Longest 
Diameter 
(mm) 
Arterial 
Perpendicular 
Diameter 
(mm) 
Arterial 
Product of the 
Perpendicular 
Diameters 
(mm
2
) 
Arterial 
Volume (cm
3
) 
1 Scan 1 1-1 28.70 14.70 421.89 3.75 
 
Scan 2 1-1 23.80 16.20 385.56 1.37 
2 Scan 1 2-1 54.40 37.10 2018.24 44.04 
 
Scan 2 2-1 72.40 59.50 4307.80 153.32 
3 Scan 1 3-1 47.50 32.00 1520.00 23.40 
 
Scan 2 3-1 86.40 49.00 4233.60 83.97 
4 Scan 1 4-1 33.50 26.70 894.45 8.15 
 
Scan 2 4-1 44.90 36.00 1616.40 17.54 
5 Scan 1 5-1 31.20 20.30 633.36 5.46 
 
Scan 2 5-1 22.30 15.30 341.19 1.64 
6 Scan 1 6-1 73.20 50.20 3674.64 73.23 
 
Scan 2 6-1 60.70 50.30 3053.21 65.66 
7 Scan 1 7-1 61.30 50.10 3071.13 102.55 
 
Scan 2 7-1 55.20 49.80 2748.96 88.18 
8 Scan 1 8-1 39.50 23.00 908.50 14.27 
 
Scan 2 8-1 38.90 28.40 1104.76 23.36 
9 Scan 1 9-1 24.90 15.70 390.93 4.22 
 
Scan 2 9-1 25.50 17.50 446.25 7.65 
10 Scan 1 10-1 50.10 44.80 2244.48 58.12 
 
Scan 2 10-1 66.30 44.30 2937.09 68.49 
11 Scan 1 11-1 71.60 54.80 3923.68 79.49 
 
Scan 2 11-1 63.60 55.60 3536.16 104.99 
12 Scan 1 12-1 37.10 29.20 1083.32 17.46 
 
Scan 2 12-1 128.10 109.20 13988.52 797.87 
13 Scan 1 13-1 25.90 25.40 657.86 6.65 
 
Scan 2 13-1 28.60 26.40 755.04 10.19 
14 Scan 1 14-1 21.40 20.00 428.00 4.33 
 
Scan 2 14-1 24.70 21.40 528.58 5.63 
15 Scan 1 15-1 22.00 17.90 393.80 4.57 
 
Scan 2 15-1 20.20 17.10 345.42 3.50 
15 Scan 1 15-2 26.50 15.80 418.70 6.19 
 
Scan 2 15-2 39.60 23.70 938.52 8.97 
16 Scan 1 16-1 19.60 16.30 319.48 3.32 
 
Scan 2 16-1 22.60 15.60 352.56 4.67 
17 Scan 1 17-1 33.90 16.20 549.18 9.98 
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Scan 2 17-1 47.90 21.50 1029.85 32.37 
18 Scan 1 18-1 56.10 49.40 2771.34 62.10 
 
Scan 2 18-1 52.70 50.70 2671.89 69.97 
19 Scan 1 19-1 32.70 21.30 696.51 5.36 
 
Scan 2 19-1 68.00 41.40 2815.20 66.84 
20 Scan 1 20-1 33.60 24.30 816.48 15.52 
 
Scan 2 20-1 41.30 34.30 1416.59 32.13 
21 Scan 1 21-1 77.10 61.00 4703.10 136.68 
 
Scan 2 21-1 116.30 53.90 6268.57 239.65 
22 Scan 1 22-1 37.60 28.60 1075.36 20.39 
 
Scan 2 22-1 62.90 29.00 1824.10 41.20 
23 Scan 1 23-1 33.50 22.40 750.40 11.48 
 
Scan 2 23-1 22.40 8.10 181.44 3.42 
24 Scan 1 24-1 20.90 15.70 328.13 2.66 
 
Scan 2 24-1 23.80 21.50 511.70 5.06 
24 Scan 1 24-2 17.40 14.30 248.82 2.52 
 
Scan 2 24-2 32.00 30.10 963.20 11.24 
25 Scan 1 25-1 20.60 18.20 374.92 3.89 
 
Scan 2 25-1 37.50 30.10 1128.75 17.24 
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Table 3b. Linear, bi-dimensional and volumetric lesion measurements on Scan 1 and Scan 2 
in the portal venous phase 
 
Subject 
Number 
Scan 
Lesion 
# 
Portal 
Venous 
Longest 
Diameter 
(mm) 
Portal Venous 
Perpendicular 
Diameter 
(mm) 
Portal Venous 
Product of the 
Perpendicular 
Diameters 
(mm
2
) 
Portal 
Venous 
Volume (cm
3
) 
1 Scan 1 1-1 22.60 18.40 415.84 1.10 
 
Scan 2 1-1 31.00 18.30 567.30 5.46 
2 Scan 1 2-1 46.70 37.30 1741.91 51.37 
 
Scan 2 2-1 70.30 57.00 4007.10 140.00 
3 Scan 1 3-1 49.50 31.00 1534.50 15.23 
 
Scan 2 3-1 69.50 58.30 4051.85 70.48 
4 Scan 1 4-1 33.10 28.70 949.97 10.12 
 
Scan 2 4-1 38.90 33.70 1310.93 16.66 
5 Scan 1 5-1 39.10 25.00 977.50 6.90 
 
Scan 2 5-1 25.20 19.10 481.32 1.39 
6 Scan 1 6-1 63.30 47.80 3025.74 77.53 
 
Scan 2 6-1 70.10 53.90 3778.39 69.43 
7 Scan 1 7-1 59.40 48.20 2863.08 103.99 
 
Scan 2 7-1 58.60 49.80 2918.28 96.90 
8 Scan 1 8-1 37.00 26.80 991.60 14.49 
 
Scan 2 8-1 50.30 38.10 1916.43 55.06 
9 Scan 1 9-1 25.60 16.10 412.16 5.75 
 
Scan 2 9-1 26.40 26.40 696.96 11.42 
10 Scan 1 10-1 59.10 47.30 2795.43 63.24 
 
Scan 2 10-1 57.10 48.80 2786.48 78.82 
11 Scan 1 11-1 73.30 55.40 4060.82 123.97 
 
Scan 2 11-1 72.40 58.10 4206.44 129.14 
12 Scan 1 12-1 40.50 31.80 1287.90 16.25 
 
Scan 2 12-1 123.10 85.00 10463.50 756.63 
13 Scan 1 13-1 25.70 25.50 655.35 5.99 
 
Scan 2 13-1 28.50 27.00 769.50 9.13 
14 Scan 1 14-1 23.50 16.50 387.75 4.96 
 
Scan 2 14-1 26.60 15.10 401.66 6.48 
15 Scan 1 15-1 23.70 22.20 526.14 5.41 
 
Scan 2 15-1 17.40 10.90 189.66 1.21 
15 Scan 1 15-2 29.30 21.80 638.74 4.78 
 
Scan 2 15-2 50.30 31.50 1584.45 13.16 
16 Scan 1 16-1 23.00 20.20 464.60 5.03 
 
Scan 2 16-1 23.80 21.20 504.56 4.84 
 16 
17 Scan 1 17-1 28.20 14.30 403.26 8.22 
 
Scan 2 17-1 47.20 29.40 1387.68 21.26 
18 Scan 1 18-1 57.00 42.60 2428.20 66.68 
 
Scan 2 18-1 57.20 47.00 2688.40 72.63 
19 Scan 1 19-1 42.10 30.50 1284.05 24.57 
 
Scan 2 19-1 46.20 35.50 1640.10 33.42 
20 Scan 1 20-1 33.70 25.90 872.83 12.96 
 
Scan 2 20-1 48.90 37.70 1843.53 38.08 
21 Scan 1 21-1 62.50 48.80 3050.00 111.09 
 
Scan 2 21-1 83.20 61.40 5108.48 202.53 
22 Scan 1 22-1 30.10 26.20 788.62 16.37 
 
Scan 2 22-1 34.30 28.80 987.84 16.92 
23 Scan 1 23-1 22.20 15.40 341.88 3.02 
 
Scan 2 23-1 18.90 12.70 240.03 0.93 
24 Scan 1 24-1 17.50 13.80 241.50 1.56 
 
Scan 2 24-1 26.30 24.70 649.61 5.86 
24 Scan 1 24-2 19.40 18.00 349.20 2.10 
 
Scan 2 24-2 32.60 26.60 867.16 11.83 
25 Scan 1 25-1 22.20 16.50 366.30 2.81 
 
Scan 2 25-1 37.70 32.10 1210.17 15.56 
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Table 3c. Summary of measurement data 
 
  Variable Min 1st Q Med 3rd Q Max Mean 
Both 
Scans 
Arterial Longest 
Diameter (mm) 
17.40 25.05 37.30 55.88 128.10 43.71 
Arterial 
Perpendicular 
Diameter (mm2) 
8.10 17.98 26.55 44.67 109.20 39.88 
Arterial Product of 
the Perpendicular 
Diameters (mm2) 
181.40 432.60 950.90 2729.70 13988.50 1773.10 
Arterial Volume 
(mm3) 
1.37 5.14 14.90 64.77 797.87 49.92 
PV Longest 
Diameter (mm) 
17.40 25.85 37.35 57.08 123.10 42.25 
PV Perpendicular 
Diameter (mm2) 
10.90 20.45 28.75 45.90 85.00 32.59 
PV Product of the 
Perpendicular 
Diameters (mm2) 
189.70 510.00 989.70 2623.30 10463.50 1687.30 
PV Arterial Volume 
(mm3) 
0.93 5.53 14.86 65.82 756.63 49.09 
                
Scan 1 
Arterial Longest 
Diameter (mm) 
17.40 25.40 33.50 48.80 77.10 38.21 
Arterial 
Perpendicular 
Diameter (mm2) 
14.30 17.10 23.00 34.55 61.00 28.35 
Arterial Product of 
the Perpendicular 
Diameters (mm2) 
248.80 420.30 750.40 1769.10 4703.10 1308.00 
Arterial Volume 
(mm3) 
2.52 4.45 9.98 33.72 136.68 27.03 
PV Longest 
Diameter (mm) 
17.50 23.60 33.10 48.10 73.30 37.37 
PV Perpendicular 
Diameter (mm2) 
13.80 18.20 25.90 34.55 55.40 28.59 
PV Product of the 
Perpendicular 
Diameters (mm2) 
241.50 414.00 872.80 1638.20 4060.80 1253.90 
PV Arterial Volume 
(mm3) 
1.10 5.00 10.12 37.97 123.97 28.35 
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Scan 2 
Arterial Longest 
Diameter (mm) 
20.20 25.10 41.30 63.25 128.10 49.21 
Arterial 
Perpendicular 
Diameter (mm2) 
8.10 21.45 30.10 49.40 109.20 35.40 
Arterial Product of 
the Perpendicular 
Diameters (mm2) 
181.40 520.10 1128.80 2876.10 13988.50 2238.20 
Arterial Volume 
(mm3) 
1.37 6.64 23.36 69.23 797.87 72.82 
PV Longest 
Diameter (mm) 
17.40 27.55 46.20 57.90 123.10 47.11 
PV Perpendicular 
Diameter (mm2) 
10.90 25.55 32.10 49.30 85.00 36.60 
PV Product of the 
Perpendicular 
Diameters (mm2) 
189.70 673.30 1387.70 2852.40 10463.50 2120.70 
PV Arterial Volume 
(mm3) 
0.93 7.81 16.92 71.56 756.63 69.82 
 
 
 
The size change (in percent) of each lesion was determined for each linear, bi-
dimensional, and volumetric measurement in both the arterial and portal venous phases.  
 
(Scan 2 lesion size – Scan 1 lesion size) x 100 = % change 
Scan 1 lesion size 
 
The percentage change of a lesion between the two scans was the data used for statistical 
analyses (Table 4). 
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Table 4a. Percent changes of linear, bi-dimensional and volumetric measurements between 
Scan 1 and Scan 2 in the arterial and portal venous phases for each lesion  
 
Subject 
Number 
Lesion 
Number 
Phase 
% Change 
Longest 
Diameter 
(mm) 
% Change 
Product of the 
Perpendicular 
Diameters 
(mm
2
) 
% Change 
Volume 
(mm
3
) 
1 1-1 A -1707.32% -861.12% -6352.47% 
1 1-1 PV 3716.81% 3642.27% 39835.62% 
2 2-1 A 3308.82% 11344.34% 24810.64% 
2 2-1 PV 5053.53% 13004.06% 17251.67% 
3 3-1 A -3439.23% -6471.52% -8473.98% 
3 3-1 PV -2958.75% -6170.55% -8911.93% 
4 4-1 A 3402.99% 8071.44% 11513.74% 
4 4-1 PV 1752.27% 3799.70% 6452.63% 
5 5-1 A -2852.56% -4613.02% -6998.35% 
5 5-1 PV -3554.99% -5076.01% -7984.63% 
6 6-1 A -1707.65% -2053.81% -1034.11% 
6 6-1 PV 1074.25% 2487.49% -1044.99% 
7 7-1 A -995.11% -1049.03% -1401.71% 
7 7-1 PV -134.68% 192.80% -681.43% 
8 8-1 A -151.90% 2160.26% 6371.86% 
8 8-1 PV 3594.59% 9326.64% 28014.50% 
9 9-1 A 240.96% 1415.09% 8120.41% 
9 9-1 PV 312.50% 6909.94% 9850.46% 
10 10-1 A 3233.53% 3085.84% 1784.16% 
10 10-1 PV -338.41% -32.02% 2462.96% 
11 11-1 A -1117.32% -987.64% 3208.12% 
11 11-1 PV -122.78% 358.60% 417.12% 
12 12-1 A 24528.30% 119126.39% 447023.14% 
12 12-1 PV 20395.06% 71244.66% 455533.75% 
13 13-1 A 1042.47% 1477.21% 5318.70% 
13 13-1 PV 1089.49% 1741.82% 5241.28% 
14 14-1 A 1542.06% 2350.00% 3005.09% 
14 14-1 PV 1319.15% 358.74% 3081.11% 
15 15-1 A -818.18% -1228.54% -2339.03% 
15 15-1 PV -2658.23% -6395.26% -7773.47% 
15 15-2 A 4943.40% 12415.09% 4500.65% 
15 15-2 PV 7167.24% 14805.87% 17548.16% 
16 16-1 A 1530.61% 1035.43% 4065.70% 
16 16-1 PV 347.83% 860.09% -385.61% 
17 17-1 A 4129.79% 8752.50% 22435.87% 
17 17-1 PV 6737.59% 24411.55% 15865.17% 
18 18-1 A -606.06% -358.85% 1266.59% 
18 18-1 PV 35.09% 1071.58% 891.87% 
19 19-1 A 10795.11% 30418.66% 114738.71% 
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19 19-1 PV 973.87% 2772.87% 3601.40% 
20 20-1 A 2291.67% 7349.97% 10697.67% 
20 20-1 PV 4510.39% 11121.30% 19381.22% 
21 21-1 A 5084.31% 3328.59% 7533.86% 
21 21-1 PV 3312.00% 6749.11% 8230.84% 
22 22-1 A 6728.72% 6962.69% 10205.50% 
22 22-1 PV 1395.35% 2526.18% 340.36% 
23 23-1 A -3313.43% -7582.09% -7017.94% 
23 23-1 PV -1486.49% -2979.12% -6932.50% 
24 24-1 A 1387.56% 5594.43% 9021.82% 
24 24-1 PV 5028.57% 16898.96% 27442.46% 
24 24-2 A 8390.80% 28710.71% 34670.11% 
24 24-2 PV 6804.12% 14832.76% 46455.15% 
25 25-1 A 8203.88% 20106.42% 34342.68% 
25 25-1 PV 6981.98% 23037.67% 45420.23% 
 
 
 
 
Table 4b. Summary of percent change data  
 
  Variable Mean 
Std. 
Dev 
Min Max 
Both 
Phases 
% Change Longest Diameter (mm) 26.75 51.87 35.55 245.28 
% Change Product of the Perpendicular 
Diameters (mm2) 
85.19 197.71 -75.82 1191.26 
% Change Volume (mm3) 268.63 863.33 -89.12 4555.34 
            
Arterial 
Phase 
% Change Longest Diameter (mm) 27.44 57.22 -34.39 245.28 
% Change Product of the Perpendicular 
Diameters (mm2) 
92.04 238.44 -75.82 1191.26 
% Change Volume (mm3) 270.75 871.80 -84.74 4470.23 
            
PV 
Phase 
% Change Longest Diameter (mm) 26.05 47.00 -35.55 203.95 
% Change Product of the Perpendicular 
Diameters (mm2) 
78.33 150.77 -63.95 712.45 
% Change Volume (mm3) 266.52 871.40 -89.12 4555.34 
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Statistical analysis 
Comparisons were made of the percentage changes for the linear measurements 
versus the bi-dimensional measurements, the linear measurements versus the volumetric 
measurements, and the bi-dimensional measurements versus the volumetric 
measurements. Comparisons were also made between the arterial phase and the portal 
venous phase. The percent changes of the linear measurements in the arterial phase were 
compared to the percent changes of the linear measurements in the portal venous phase; 
the percent changes of the bi-dimensional measurements in the arterial phase were 
compared to the percent changes of the bi-dimensional measurements in the portal 
venous phase; and the percent changes of the volumetric measurements in the arterial 
phase were compared to the percent changes of the volumetric measurements in the 
portal venous phase. A Wilcoxon signed-rank test was used to compare differences in 
measurements due to the small sample size and the lack of normality in the data 
distribution. A simple correlation was run to compare the different measurement types 
within each phase, as well as to compare the same measurement types between phases. 
Additionally, a paired t test with a 95% confidence interval was performed on the 
measurements between phases. All statistical analyses were performed using statistical 
software (STATA version 11.2, StataCorp, College Station, TX, USA). 
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RESULTS 
 
Comparison of linear, bi-dimensional and volumetric percent changes 
Significant differences between the percent changes of the three measurement 
types were observed. For linear measurements versus bi-dimensional measurements, the 
Wilcoxon signed-rank test (Table 5) showed a p = 0.0001 and the bi-dimensional percent 
changes on average 2.5 times (range, .02 - 29.54) greater, in either the positive or 
negative direction, than the linear percent changes. For bi-dimensional measurements 
versus the volumetric measurements, p = 0.0004 and the volumetric percent changes were 
on average 5.2 times (range, .09 - 77.93) greater than the bi-dimensional percent changes. 
For linear measurements versus volumetric measurements, p = 0.0000 and the volumetric 
percent changes were on average 5.8 times (range, .09 - 42.95) greater than the linear 
percent changes. 
 
 
Table 5. Wilcoxon signed-rank test results 
Percent Change Comparison P - Value 
Linear vs Bi-dimensional 0.0001 
Linear vs Volumetric 0.0000 
Bi-dimensional vs Volumetric 0.0004 
Arterial Linear vs PV Linear 0.7916 
Arterial Bi-dimensional vs PV Bi-dimensional 0.4004 
Arterial Volumetric vs PV Volumetric 0.4711 
  
 
 
The correlation assessment showed all positive correlations between the different 
measurement types (Table 6). The lowest correlations between two different 
 23 
measurement types were linear versus volumetric in both phases with a correlation of 
0.8679 in arterial phase and 0.8434 in portal venous phase.  
 
 
Table 6. Correlations 
Percent Change Comparison Correlation 
Arterial Linear vs Arterial Bi-dimensional 0.9333 
Arterial Linear vs Arterial Volumetric 0.8679 
Arterial Bi-dimensional vs Arterial Volumetric 0.9760 
PV Linear vs PV Bi-dimensional 0.9675 
PV Linear vs PV Volumetric 0.8434 
PV Bi-dimensional vs PV Volumetric 0.9029 
Arterial Linear vs PV Linear 0.8340 
Arterial Bi-dimensional vs PV Bi-dimensional 0.9013 
Arterial Volumetric vs PV Volumetric 0.9591 
 
 
Comparison of arterial and portal venous percent changes 
The Wilcoxon signed-rank test did not show a significant difference between the 
percent changes of the same type of measurement in the arterial and portal venous phases 
(Table 5). The paired t test showed similar results with the two-tailed p-values. For the 
linear measurements the p-value = 0.8220, for the bi-dimensional measurements the p-
value = 0.5631, and for the volumetric measurements the p-value = 0.9305.  
All correlations between the arterial and portal venous phases were positive 
(Table 6). For the linear measurements the correlations was 0.8340, for the bi-
dimensional measurements 0.9013 and for the volumetric measurements 0.9591.  
  
 24 
DISCUSSION 
 
 This study provides evidence that rejects the null hypothesis that there is 
no statistically significant difference in using linear, bi-dimensional and volumetric 
measurements for calculating percent change of HCC lesions on MRI. 
While most current criteria suggest using CT over MRI for tumor measurements, 
research indicates that MRI is more sensitive for visualizing lesions with a longest 
diameter of 2cm or larger. A number of studies have been performed comparing CT 
versus MRI, however, there have been inconclusive results with regards to whether or not 
CT is more sensitive than MRI for delineating lesions with a longest diameter less than 
2cm.8 A total of 4 lesions identified for this study had a longest diameter measurement of 
<2cm on Scan 1 in the arterial and/or the portal venous phase (lesion 24-2 measured 
<2cm on both phases). Visibility of the lesions was an inclusion requirement for this 
study: therefore, all lesions were able to be reviewed on both Scan 1 and Scan 2. 
Consequently, it was not a concern that the smaller lesion measurement was influenced 
by MRI sensitivity. The scans were also assessed for image quality issues, such as 
breathing artifacts, which can be an issue, particularly in subjects with ascites.8 The 3D 
imaging series allowed for avoidance of partial volume artifacts. There were no image 
quality concerns on the scans that would affect the accuracy of lesion measurements.   
A major advantage of measuring on the 3D-GRE series is that it provides detailed 
anatomical and pathological information.23 This is important when delineating HCC 
lesions because it is often difficult to distinguish tumor tissue from the cirrhotic liver 
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tissue. The diffuse, infiltrative nature of the disease in the cirrhotic tissue and the 
pathology of the cirrhotic liver can affect the visibility of the tumor.9,29 There are 
different types of HCC which have unique imaging characteristics, as well as, differences 
in clinical presentation and prognosis. A large majority of HCC cases have nodular 
lesions, with one or more focal well-circumscribed lesions that present with the arterial 
enhancement and portal venous washout. Conversely, infiltrative HCC (I-HCC) presents 
with large permeative areas of continuous tumor, an ill-defined growth pattern and a lack 
of reliability of arterial hypervascularity.30,31 While the specific type of HCC was not 
listed in the available clinical information, all lesions selected for measurement appeared 
nodular and discrete on both scans and were easily distinguishable from the cirrhotic liver 
tissue. This study does not provide comparative data for infiltrative lesions or lesions that 
merge together when the liver disease becomes extensive.  
The selected lesions were measured only once, by a single reader, on both the 
arterial phase and portal venous phase of each scan. An intra-reader variability analysis 
was not performed. Previous studies have validated the reproducibility of both linear and 
bi-dimensional measurements of tumors.25,27 However, additional data studying the 
ability to repeat these measurements on HCC lesions would be beneficial. There is little 
data regarding the variability of volumetric measurements of HCC lesions. In future 
studies, a full inter- and intra-reader variability analysis should be performed for all 
measurement types for HCC.  
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All comparisons of measurement percent changes from Scan 1 to Scan 2 (linear 
versus volumetric, linear versus bi-dimensional, bi-dimensional versus volumetric) are 
significantly different for the data set as a whole which includes both the arterial phase 
measurements and the portal venous phase measurements. 
 27 
 
Figure 4: As outliers, Subject 12 has been removed from all charts and Subject 19 has been 
removed from charts A and E. A) The difference in % changes of linear and volumetric 
measurements in the Arterial phase per lesion. B) The difference in % changes of linear and 
volumetric measurements in the Portal Venous phase per lesion. C) The difference in % 
changes of linear and bi-dimensional measurements in the Arterial phase per lesion. D) The 
difference in % changes of linear and bi-dimensional measurements in the Portal Venous 
phase per lesion. E) The difference in % changes of bi-dimensional and volumetric 
measurements in the Arterial phase per lesion. F) The difference in % changes of bi-
dimensional and volumetric measurements in the Portal Venous phase per lesion. 
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When plotted (Fig. 4), the most distinct differences in percent changes are between the 
linear measurements and the volumetric measurements. 
The majority of the differences in percent change from Scan 1 to Scan 2 are in the 
negative range, which shows that these volumetric percent changes were larger than the 
linear percent changes. In regards to positive changes, the volumetric measurements 
showed a larger tumor decrease than the linear measurements. When reviewing the 
findings of the full statistical analysis, they are in agreement with previous studies 
comparing all three measurement types for various indications.32,33,34 The Wilcoxon 
signed rank test showed significant differences between all of the different measurement 
types, particularly with the linear versus the volumetric (Table 5). While not a 
significance test, the correlation assessment supports this finding with the lowest 
correlations being between the linear versus volumetric measurements in both phases 
(Table 6).  
The percent decreases of the volumetric measurements between Scan 1 and Scan 
2 are much larger than the percent decreases of the linear measurements. While this result 
is statistically significant, it will not be significant in determining tumor response until 
there is a consensus regarding volumetric criteria.35 Per RECIST, a >30% decrease in 
tumor diameter from baseline is considered a partial response (PR). In one study 
comparing RECIST with volumetric algorithms, a threshold of 65% volumetric decrease 
was used when determining PR for the 3D measurements.36 When this threshold is 
applied to the study data, three lesions measured in the portal venous phase and two 
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lesions measured in arterial phase can be considered PR volumetrically, while the change 
in longest diameter is considered stable disease (SD). These scenarios illustrate how 
volumetric measurements can capture an asymmetric decrease in tumor volume while the 
change in the one-dimensional longest diameter can appear stable. There is no agreement 
in regards to whether or not an observed difference like this in tumor response would lead 
to clinically relevant differences in classifying response. 
The study mentioned previously also defined a threshold of 44% volumetric 
increase when determining progressive disease (PD) for 3D measurements.36 When this 
threshold is applied to this study data, three lesions measured in the portal venous phase 
and three lesions measured in the arterial phase are considered PD volumetrically, while 
the change in longest diameter is considered SD. There was one case where the lesion 
measured in the portal venous phase would qualify for PD by RECIST (>20% increase in 
the longest diameter) but would only be considered SD volumetrically. The differences in 
the assessment of PD are important both clinically and in clinical trials.  
While linear and bi-dimensional tumor assessment criteria have become widely 
accepted, there are a number of limitations to consider that can be minimized by using 
volumetric measurements. A major limitation of a linear or bi-dimensional assessment is 
that measurements are only allowed on the axial plane in criteria such as RECIST. Some 
HCC lesions have complex morphology and show asymmetric growth that can be missed 
with the linear and bi-dimensional criteria. These criteria can only accurately assess 
tumor response when the lesions are spherical and grow in a spherical fashion.43,44 Lesion 
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orientation or slice locations are not taken into consideration, nor are differences in 
machinery or imaging parameters, such as slice thickness, between visits.45 Therefore, 
these measurements are estimating tumor change rather than illustrating true tumor 
volume change. This can make it especially difficult to account for small volume changes 
which could easily be accounted for by measuring the full lesion volume. Another 
limitation of linear and bi-dimensional criteria is measurement variability. A recent 
variability study comparing linear, bi-dimensional, and volumetric measurements showed 
that there was less measurement variability for volumetric measurements of lesions with 
complex shapes, which is consistent with a number of similar studies.46 Volumetric 
measurements can provide more accurate and reproducible data.47 More objective data 
can also be provided as the entire tumor is being measured rather than a slice of the tumor 
being subjectively chosen and measured by a reader.45,47 
It is important to take note that this study is only analyzing percent changes of 
individual lesions rather than the whole tumor burden for the subject. For RECIST, the 
sum of diameters for all of the selected measureable lesions is used to calculate the 
percent change that can determine response or progression. This means that while one 
lesion is decreasing in size, another lesion may be increasing in size, thus, the net result 
of these tumor changes may then be SD. Further study is needed to compare the percent 
changes of the tumor burden for full volume versus the sum of diameters. 
Another important consideration that is not included in this study is the 
heterogeneity of HCC lesions. In liver cancer, response to treatment may not only result 
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in reduction of tumor size, but also tumor necrosis, reduction in tumor vascularization, 
cavitation and colliquation of the tumor.37,38 The tumor measurements included the tumor 
as a whole regardless of tissue viability. This could account for the lack of significance 
between the percent changes for the same lesion measured on the arterial phase versus the 
portal venous phase (Fig. 5).  
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Figure 5: A) The difference in % changes of linear measurements on the Arterial and Portal 
Venous phases. B) The difference in % changes of bi-dimensional measurements on the 
Arterial and Portal Venous phases. Outlier subjects 12 and 19 removed. C) The difference 
in % changes of volumetric measurements on the Arterial and Portal Venous phases. 
Outlier subjects 1 and 19 removed. 
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The arterial and portal venous phase measurements were compared in this study 
to evaluate if HCC’s unique enhancement pattern has any effect on quantifying tumor 
change, as is suggested in the mRECIST criterion.26 Even though the specific guidelines 
within the mRECIST criterion defining the type of tumor tissue that should be included in 
the measurements were followed, there was no significant difference seen between the 
arterial and portal venous phase percent changes. mRECIST results are currently not 
accepted as clinical trial results for HCC without RECIST data as well, so this finding 
does not affect current guidelines. It could, however, serve as an argument to eliminate an 
mRECIST evaluation. Additional research for volumetric measurements may still prove 
the arterial phase useful in analyzing tumor change. It would be necessary to define the 
types of tumor tissue that should be included in the volumetric measurements and then 
compare the viable volumetric tissue measurements in both the arterial and portal venous 
phases. This may prove difficult, as the assessment of viable tissue could be very 
subjective, therefore, a great deal of investigation will be required to determine if these 
hypothetical volumetric guidelines are reproducible.  
In conclusion, the differences in the percent changes when comparing the 
measurement types is statistically significant, particularly when comparing linear and 
volumetric measurements, thus rejecting the null hypothesis. Further studies establishing 
volumetric review criteria and comparing those guidelines to accepted criteria, such as 
RECIST, are warranted. Establishing a reproducible volumetric criterion could lead to 
improvements in the implementation of clinical trials and the better handling of patient 
treatment.   
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